SHON Expression Predicts Response and Relapse Risk of Breast Cancer Patients After Anthracycline-based Combination Chemotherapy or Tamoxifen Treatment
aut.relation.endpage | 745 | |
aut.relation.issue | 7 | en_NZ |
aut.relation.journal | British Journal of Cancer | en_NZ |
aut.relation.startpage | 728 | |
aut.relation.volume | 120 | en_NZ |
aut.researcher | Li, Yan | |
dc.contributor.author | Abdel-Fatah, TMA | en_NZ |
dc.contributor.author | Broom, RJ | en_NZ |
dc.contributor.author | Lu, J | en_NZ |
dc.contributor.author | Moseley, PM | en_NZ |
dc.contributor.author | Huang, B | en_NZ |
dc.contributor.author | Li, L | en_NZ |
dc.contributor.author | Liu, S | en_NZ |
dc.contributor.author | Chen, L | en_NZ |
dc.contributor.author | Ma, RZ | en_NZ |
dc.contributor.author | Cao, W | en_NZ |
dc.contributor.author | Wang, X | en_NZ |
dc.contributor.author | Li, Y | en_NZ |
dc.contributor.author | Perry, JK | en_NZ |
dc.contributor.author | Aleskandarany, M | en_NZ |
dc.contributor.author | Nolan, CC | en_NZ |
dc.contributor.author | Rakha, EA | en_NZ |
dc.contributor.author | Lobie, PE | en_NZ |
dc.contributor.author | Chan, SYT | en_NZ |
dc.contributor.author | Ellis, IO | en_NZ |
dc.contributor.author | Hwang, LA | en_NZ |
dc.contributor.author | Lane, DP | en_NZ |
dc.contributor.author | Green, AR | en_NZ |
dc.contributor.author | Liu, DX | en_NZ |
dc.date.accessioned | 2022-07-29T03:36:48Z | |
dc.date.available | 2022-07-29T03:36:48Z | |
dc.date.copyright | 2019 | en_NZ |
dc.date.issued | 2019 | en_NZ |
dc.description.abstract | Background: SHON nuclear expression (SHON-Nuc + ) was previously reported to predict clinical outcomes to tamoxifen therapy in ERα + breast cancer (BC). Herein we determined if SHON expression detected by specific monoclonal antibodies could provide a more accurate prediction and serve as a biomarker for anthracycline-based combination chemotherapy (ACT). Methods: SHON expression was determined by immunohistochemistry in the Nottingham early-stage-BC cohort (n = 1,650) who, if eligible, received adjuvant tamoxifen; the Nottingham ERα − early-stage-BC (n = 697) patients who received adjuvant ACT; and the Nottingham locally advanced-BC cohort who received pre-operative ACT with/without taxanes (Neo-ACT, n = 120) and if eligible, 5-year adjuvant tamoxifen treatment. Prognostic significance of SHON and its relationship with the clinical outcome of treatments were analysed. Results: As previously reported, SHON-Nuc + in high risk/ERα + patients was significantly associated with a 48% death risk reduction after exclusive adjuvant tamoxifen treatment compared with SHON-Nuc − [HR (95% CI) = 0.52 (0.34–0.78), p = 0.002]. Meanwhile, in ERα − patients treated with adjuvant ACT, SHON cytoplasmic expression (SHON-Cyto + ) was significantly associated with a 50% death risk reduction compared with SHON-Cyto − [HR (95% CI) = 0.50 (0.34–0.73), p = 0.0003]. Moreover, in patients received Neo-ACT, SHON-Nuc − or SHON-Cyto + was associated with an increased pathological complete response (pCR) compared with SHON-Nuc + [21 vs 4%; OR (95% CI) = 5.88 (1.28–27.03), p = 0.012], or SHON-Cyto − [20.5 vs. 4.5%; OR (95% CI) = 5.43 (1.18–25.03), p = 0.017], respectively. After receiving Neo-ACT, patients with SHON-Nuc + had a significantly lower distant relapse risk compared to those with SHON-Nuc − [HR (95% CI) = 0.41 (0.19–0.87), p = 0.038], whereas SHON-Cyto + patients had a significantly higher distant relapse risk compared to SHON-Cyto − patients [HR (95% CI) = 4.63 (1.05–20.39), p = 0.043]. Furthermore, multivariate Cox regression analyses revealed that SHON-Cyto + was independently associated with a higher risk of distant relapse after Neo-ACT and 5-year tamoxifen treatment [HR (95% CI) = 5.08 (1.13–44.52), p = 0.037]. The interaction term between ERα status and SHON-Nuc + (p = 0.005), and between SHON-Nuc + and tamoxifen therapy (p = 0.007), were both statistically significant. Conclusion: SHON-Nuce + in tumours predicts response to tamoxifen in ERα + BC while SHON-Cyto + predicts response to ACT. | en_NZ |
dc.identifier.citation | British Journal of Cancer 120, 728–745 (2019). https://doi.org/10.1038/s41416-019-0405-x | |
dc.identifier.doi | 10.1038/s41416-019-0405-x | en_NZ |
dc.identifier.issn | 0007-0920 | en_NZ |
dc.identifier.issn | 1532-1827 | en_NZ |
dc.identifier.uri | https://hdl.handle.net/10292/15328 | |
dc.publisher | Springer Nature | |
dc.relation.uri | https://www.nature.com/articles/s41416-019-0405-x | |
dc.rights | © 2019, Cancer Research UK. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) | |
dc.rights.accessrights | OpenAccess | en_NZ |
dc.subject | Molecular medicine; Predictive markers; Prognostic markers | |
dc.title | SHON Expression Predicts Response and Relapse Risk of Breast Cancer Patients After Anthracycline-based Combination Chemotherapy or Tamoxifen Treatment | en_NZ |
dc.type | Journal Article | |
pubs.elements-id | 354783 | |
pubs.organisational-data | /AUT | |
pubs.organisational-data | /AUT/Faculty of Health & Environmental Science | |
pubs.organisational-data | /AUT/Faculty of Health & Environmental Science/School of Public Health & Interdisciplinary Studies | |
pubs.organisational-data | /AUT/Faculty of Health & Environmental Science/School of Public Health & Interdisciplinary Studies/Biosciences Department | |
pubs.organisational-data | /AUT/Faculty of Health & Environmental Science/School of Science | |
pubs.organisational-data | /AUT/Faculty of Health & Environmental Science/School of Science/Biomedicine & Medical Diagnostics Department | |
pubs.organisational-data | /AUT/PBRF | |
pubs.organisational-data | /AUT/PBRF/PBRF Health and Environmental Sciences | |
pubs.organisational-data | /AUT/PBRF/PBRF Health and Environmental Sciences/HA Science 2018 PBRF | |
pubs.organisational-data | /AUT/PBRF/PBRF Health and Environmental Sciences/HI Interprofessional 2018 PBRF |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemother.pdf
- Size:
- 2.02 MB
- Format:
- Adobe Portable Document Format
- Description:
- Journal article
License bundle
1 - 1 of 1
Loading...
- Name:
- AUT Grant of Licence for Tuwhera Jun 2021.pdf
- Size:
- 360.95 KB
- Format:
- Adobe Portable Document Format
- Description: